Davis Capital Management
RVMD icon

Davis Capital Management’s Revolution Medicines RVMD Stock Holding History

Davis Capital Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$821 Hold
4
– – ﹤0.01% 540
2026
Q2 		$749 Buy
+4
New +$584 ﹤0.01% 539

Other funds holding RVMD

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Mass General Brigham
Mass General Brigham Somerville, Massachusetts $456M AUM 27.51% 1-Year Est. Return
Chicago Capital
Chicago Capital Chicago, Illinois $4.32B AUM 31.14% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Parnassus Investments
Parnassus Investments San Francisco, California $33.8B AUM 31.08% 1-Year Est. Return
Loftus Peak
Loftus Peak Sydney, Australia $781M AUM
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Davis Capital Management's RVMD Position: Q3 2026 in Review

Davis Capital Management held its Revolution Medicines (RVMD) position steady in Q3 2026 at 4 shares worth $821. The position accounts for ﹤0.01% of the portfolio, ranked #540.

Davis Capital Management first reported a position in RVMD in Q2 2026 and has held it in 2 quarters since. 268 funds tracked by Wall St. Rank hold RVMD as of Q3 2026.

  • Davis Capital Management held 4 shares of Revolution Medicines worth $821 as of Q3 2026.
  • Davis Capital Management left its Revolution Medicines share count unchanged in Q3 2026.
  • Revolution Medicines made up ﹤0.01% of Davis Capital Management's portfolio in Q3 2026, its #540 holding.
  • Davis Capital Management first reported a position in Revolution Medicines in Q2 2026 and has held it in 2 quarters since.
  • 268 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.